{"id":1074,"date":"2011-01-20T00:56:06","date_gmt":"2011-01-20T06:56:06","guid":{"rendered":"https:\/\/waiting.com\/blog\/?p=1074"},"modified":"2011-01-20T00:56:06","modified_gmt":"2011-01-20T06:56:06","slug":"fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure","status":"publish","type":"post","link":"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html","title":{"rendered":"FDA To Consider How Important Tests Are for Alzheimer’s, A Disease With No Cure"},"content":{"rendered":"\r\n

Depending on who you believe in the media, we are coming closer to having methods to determine if someone has Alzheimer’s disease — or federal regulators are unimpressed with at least one of the potential solutions.<\/p>\r\n

The New York Times Wednesday ran an upbeat story with the headline “Two Tests Could Aid In Risk Assessment\u00a0And Early Diagnosis of Alzheimer’s.”\u00a0\u00a0\u00a0\u00a0<\/p>\r\n

http:\/\/www.nytimes.com\/2011\/01\/19\/health\/research\/19alzheimers.html?_r=1&ref=us<\/a><\/p>\r\n

The Times noted that one new\u00a0study had evaluated\u00a0a new kind of brain scan that detects the plaques in the brain that are characteristic of Alzheimers’.\u00a0On Thursday\u00a0a Food and Drug Administration committee is scheduled to review that study and recommend\u00a0whether that test should get the go-ahead to be\u00a0marketed.<\/p>\r\n

The new brain scan involves what The Times described as\u00a0a dye\u00a0created by Avid Radiopharmaceuticals, which is part of Eli Lilly & Co. That dye\u00a0is supposed to attach to the plaque in the brain, beta amyloid, “lighting” it up\u00a0so that it becomes visible\u00a0in PET scans.<\/p>\r\n

In contrast to the upbeat report in The Times, The Wall Street Journal said the dye that finds plaque, which it named as the\u00a0drug\u00a0Amyvid,\u00a0was being given a dim eye by the FDA committee. The Journal, in a story headlined “FDA Skeptical About Detecting Alzheimer’s,”\u00a0reported that two FDA reviewers\u00a0are recommending that Amyvid not be approved. \u00a0\u00a0\u00a0\u00a0<\/p>\r\n

http:\/\/online.wsj.com\/article\/SB10001424052748704678004576090320296403228.html?KEYWORDS=alzheimer%27s<\/a><\/p>\r\n

At least two FDA reviewers questioned the need for the new scan since there isn’t even a cure for Alzheimer’s yet. And according to The Journal, the first question the FDA will be asked to address Thursday is “whether knowledge of brain amyloid plaque\u00a0would have ‘clinical usefulness.'”\u00a0<\/p>\r\n

\u00a0<\/p>\r\n

A second study investigated whether\u00a0a blood test can detect the presence of the protein that comprises Alzheimer’s plaque, beta amyloid, according to The Times.\u00a0<\/p>\r\n

The studies were reported Wednesday in The\u00a0Journal of the American Medical Association.\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\r\n

http:\/\/jama.ama-assn.org\/content\/305\/3\/261.full<\/a><\/p>\r\n

\u00a0<\/p>\r\n

\u00a0<\/p>\r\n","protected":false},"excerpt":{"rendered":"

Depending on who you believe in the media, we are coming closer to having methods to determine if someone has Alzheimer’s disease — or federal regulators are unimpressed with at least one of the potential solutions. The New York Times Wednesday ran an upbeat story with the headline “Two Tests Could Aid In Risk Assessment\u00a0And […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[732,615],"class_list":["post-1074","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-alzheimers-detection","tag-alzheimers-disease"],"yoast_head":"\nFDA To Consider How Important Tests Are for Alzheimer's, A Disease With No Cure - Brain Injury Lawyer Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA To Consider How Important Tests Are for Alzheimer's, A Disease With No Cure - Brain Injury Lawyer Blog\" \/>\n<meta property=\"og:description\" content=\"Depending on who you believe in the media, we are coming closer to having methods to determine if someone has Alzheimer’s disease — or federal regulators are unimpressed with at least one of the potential solutions. The New York Times Wednesday ran an upbeat story with the headline “Two Tests Could Aid In Risk Assessment\u00a0And […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html\" \/>\n<meta property=\"og:site_name\" content=\"Brain Injury Lawyer Blog\" \/>\n<meta property=\"article:published_time\" content=\"2011-01-20T06:56:06+00:00\" \/>\n<meta name=\"author\" content=\"Gordon Johnson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gordon Johnson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2011\\\/01\\\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2011\\\/01\\\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html\"},\"author\":{\"name\":\"Gordon Johnson\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#\\\/schema\\\/person\\\/3db3864e6ca028327e090439e0b4b262\"},\"headline\":\"FDA To Consider How Important Tests Are for Alzheimer’s, A Disease With No Cure\",\"datePublished\":\"2011-01-20T06:56:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2011\\\/01\\\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html\"},\"wordCount\":356,\"commentCount\":0,\"keywords\":[\"Alzheimer's detection\",\"Alzheimer's disease\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/waiting.com\\\/blog\\\/2011\\\/01\\\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2011\\\/01\\\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html\",\"url\":\"https:\\\/\\\/waiting.com\\\/blog\\\/2011\\\/01\\\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html\",\"name\":\"FDA To Consider How Important Tests Are for Alzheimer's, A Disease With No Cure - Brain Injury Lawyer Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#website\"},\"datePublished\":\"2011-01-20T06:56:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#\\\/schema\\\/person\\\/3db3864e6ca028327e090439e0b4b262\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/waiting.com\\\/blog\\\/2011\\\/01\\\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/waiting.com\\\/blog\\\/\",\"name\":\"Brain Injury Lawyer Blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/waiting.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/waiting.com\\\/blog\\\/#\\\/schema\\\/person\\\/3db3864e6ca028327e090439e0b4b262\",\"name\":\"Gordon Johnson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g\",\"caption\":\"Gordon Johnson\"},\"sameAs\":[\"http:\\\/\\\/tbilaw.com\"],\"url\":\"https:\\\/\\\/waiting.com\\\/blog\\\/author\\\/gjohnson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA To Consider How Important Tests Are for Alzheimer's, A Disease With No Cure - Brain Injury Lawyer Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html","og_locale":"en_US","og_type":"article","og_title":"FDA To Consider How Important Tests Are for Alzheimer's, A Disease With No Cure - Brain Injury Lawyer Blog","og_description":"Depending on who you believe in the media, we are coming closer to having methods to determine if someone has Alzheimer’s disease — or federal regulators are unimpressed with at least one of the potential solutions. The New York Times Wednesday ran an upbeat story with the headline “Two Tests Could Aid In Risk Assessment\u00a0And […]","og_url":"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html","og_site_name":"Brain Injury Lawyer Blog","article_published_time":"2011-01-20T06:56:06+00:00","author":"Gordon Johnson","twitter_misc":{"Written by":"Gordon Johnson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html#article","isPartOf":{"@id":"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html"},"author":{"name":"Gordon Johnson","@id":"https:\/\/waiting.com\/blog\/#\/schema\/person\/3db3864e6ca028327e090439e0b4b262"},"headline":"FDA To Consider How Important Tests Are for Alzheimer’s, A Disease With No Cure","datePublished":"2011-01-20T06:56:06+00:00","mainEntityOfPage":{"@id":"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html"},"wordCount":356,"commentCount":0,"keywords":["Alzheimer's detection","Alzheimer's disease"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html#respond"]}]},{"@type":"WebPage","@id":"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html","url":"https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html","name":"FDA To Consider How Important Tests Are for Alzheimer's, A Disease With No Cure - Brain Injury Lawyer Blog","isPartOf":{"@id":"https:\/\/waiting.com\/blog\/#website"},"datePublished":"2011-01-20T06:56:06+00:00","author":{"@id":"https:\/\/waiting.com\/blog\/#\/schema\/person\/3db3864e6ca028327e090439e0b4b262"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/waiting.com\/blog\/2011\/01\/fda-to-consider-how-important-tests-are-for-alzheimers-a-disease-with-no-cure.html"]}]},{"@type":"WebSite","@id":"https:\/\/waiting.com\/blog\/#website","url":"https:\/\/waiting.com\/blog\/","name":"Brain Injury Lawyer Blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/waiting.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/waiting.com\/blog\/#\/schema\/person\/3db3864e6ca028327e090439e0b4b262","name":"Gordon Johnson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ed4f3ab71dec1a856724f965e0fb35e567125a9a212a401c3cf9357dd1b8c83d?s=96&d=mm&r=g","caption":"Gordon Johnson"},"sameAs":["http:\/\/tbilaw.com"],"url":"https:\/\/waiting.com\/blog\/author\/gjohnson"}]}},"_links":{"self":[{"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/posts\/1074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/comments?post=1074"}],"version-history":[{"count":12,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/posts\/1074\/revisions"}],"predecessor-version":[{"id":1086,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/posts\/1074\/revisions\/1086"}],"wp:attachment":[{"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/media?parent=1074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/categories?post=1074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/waiting.com\/blog\/wp-json\/wp\/v2\/tags?post=1074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}